Weight-loss jabs on NHS may be rolled out ‘in high streets and shopping centres'
The 10-year plan for the health service says there is a need to expand access to weight-loss services and treatments and bring them closer to where people live and work.
It says the Government will work with industry 'to test innovative models of delivering weight loss services and treatments to patients effectively and safely' in convenient locations, which may include 'on the high street, or at any out-of-town shopping centre'.
Digital-only models, where everything is done and managed online, may also be put in place, the plan says.
Furthermore, companies will not just paid if people lose weight, 'but if that also translates into outcomes that really matter for patients, such as fewer heart attacks, strokes or cancer diagnoses'.
Earlier, Health Secretary Wes Streeting said weight-loss jabs should be available according to need, not the ability to pay.
At the moment, people with a body mass index (BMI) of 35 or more, or 30 but with a linked health condition, can be prescribed jabs on the NHS through specialist weight-management services.
Other people are paying hundreds of pounds a month to get the jabs privately.
Mr Streeting told LBC radio: 'Weight-loss jabs are the talk of the House of Commons tea rooms, half my colleagues are on them and are judging the rest of us saying 'you lot should be on them'.
'And the thing is, if you can afford these weight loss jabs, which can be over 200 quid a month, well that's all right for you.
'But most people in this country haven't got a spare two and a half grand a year and often the people who have the worst and most challenging obesity also have the lowest income.
'So I'm bringing to weight loss jabs the principle of fairness which has underpinned the NHS.
'It should be available based on need and not the ability to pay.
'And that's what we're going to do on weight-loss jabs, as well as a number of other things, including people getting more fit, more active, supporting people on diet and nutrition….that's the bit of the weight-loss jab debate that sometimes gets lost.
'It's not that you can have some weight-loss jabs and stuff your face with Jaffa cakes…'
He said obesity cost the NHS billions a year, adding that taxes have been going 'up and up' to pay for the health service.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Worst of hay fever season could be around the corner, expert warns
Hay fever sufferers in Oxfordshire must not be complacent in treating symptoms this summer amid an outburst of weed pollen in the coming weeks, a consultant has warned. Ear, nose, and throat specialist Ali Qureishi has urged people to continue managing their hay fever with daily antihistamines or nasal steroid sprays. He said: "It's been an exceptionally dry spring, so our advice to anyone who suffers from hay fever is to keep taking your one-a-day antihistamine tablets or topical nasal steroid spray because the worst symptoms could still be yet to come." Ali Qureishi (Image: Fortitude Communications) The warning comes as the UK enters the final stage of hay fever season, dominated by weed pollen from plants such as ragweed, dock weed, and mugwort. Mr Qureishi said: "Our hay fever season typically starts in late March, and ends in September. "Within that period, our exposure to tree, grass, and weed pollen can vary based on the month and other factors such as temperature, rainfall, and wind conditions." Simple steps can help to reduce exposure, such as keeping windows closed on high pollen count days, drying clothes indoors, wearing sunglasses outdoors, and washing hands regularly. Mr Qureishi also recommended a year-round approach for those with ongoing symptoms, taking an antihistamine tablet everyday. Earlier this year, Mr Qureishi was confirmed as one of the medical professionals to partner with Welbeck Health Partners ahead of the launch of its Oxford clinic next year.
Yahoo
an hour ago
- Yahoo
Aid groups warn of attacks on Sudan's hospitals as disease outbreaks and atrocities mount
CAIRO (AP) — Humanitarian organizations are sounding the alarm over attacks on healthcare facilities across Sudan, warning that they are happening amid what they describe as ongoing mass atrocities against civilians. Doctors without Borders — also known as Médecins Sans Frontières or MSF — said Thursday that 70% of medical facilities in Sudan have either closed or are barely operational with no end to the war in sight. Sudan's civil war broke out in April 2023 after simmering tensions between the Sudanese army and its paramilitary Rapid Support Forces (RSF), escalated to fighting across the country. Some 40,000 people have been killed and nearly 13 million displaced, including to other countries, according to U.N. agencies. War has left many facing food insecurity and risk of famine and exposure to disease outbreaks like cholera, which remains hard to contain due to Sudan's collapsed healthcare system. In a report released Thursday titled 'Besieged, Attacked, Starved', MSF warned that access to healthcare is nearly impossible due to systematic attacks, while the remaining operational facilities remain under constant threat. 'We call to all warring parties to stop violence against the civilian health facilities and civilian infrastructure and to facilitate a large-scale humanitarian response,' said Michel-Olivier Lacharité, MSF's head of emergency operations in a news conference presenting the report. Echoing MSF's concerns, Save the Children, warned Thursday that attacks on hospitals nearly tripled after two years of war. The group said in a statement that at least 933 people, including children, were killed during the first half of 2025. This figure is a 60-fold increase over the deaths recorded during the same period of the previous year, according to the group. Those killed were either seeking medical care or accompanying a loved one in a hospital. Major hospitals, clinics, health facilities, ambulances and medical convoys all saw fatal attacks in a country where half the population requires humanitarian assistance, according to Save the Children. 'We are concerned that in most cases, the hospitals that have come under fire also happen to be the only remaining hospitals in those areas, putting healthcare out of reach for millions, including displaced people,' said Francesco Lanino, deputy country director of programs and operations for Save the Children in Sudan. MSF particularly warned against violence in El Fasher city, the capital of North Darfur province, that made it near impossible for residents there and nearby displacement camps to access healthcare. As of April, only one hospital with surgical capacity remained partially operational, serving an estimated population of over one million. Over the past year, many patients and their caretakers have been killed while inside an MSF-supported medical facility. MSF urged the warring parties to 'halt indiscriminate and ethnically targeted violence and facilitate an immediate large-scale humanitarian response', particularly referring to threats of attacks on the hundreds of thousands of people in El Fasher, where fighting intensified since May 2024. Last month, Sudan's military accepted a U.N. proposal for a week-long ceasefire in El Fasher to allow aid delivery. However, the RSF did not explicitly agree to the truce and engaged in renewed clashes with the army in the southern part of the city this week. MSF urged the international community — especially countries engaging with both the Sudanese army and the RSF — to take stronger action to address the crisis in Sudan. 'They must use all the leverage to prevent further mass atrocities. They must place protection of civilians at the core of their engagement with the warring parties,' said Christopher Lockyear, secretary general of MSF International, on Thursday.
WebMD
an hour ago
- WebMD
FDA Greenlights New Treatment for Advanced Blood Cancer
July 3, 2025 — A new treatment has received a quick federal nod for a common blood cancer, which could affect more than 36,000 people and result in around 12,000 deaths in the U.S. this year alone. The drug, known as linvoseltamab but sold under the name Lynozyfic, is for adults with multiple myeloma whose cancer has returned or isn't responding well to treatment, especially if they've already tried at least four other treatments. Lynozyfic is said to offer a flexible dosing plan tailored to each patient's needs. In multiple myeloma, plasma cells (a type of white blood cell that makes antibodies against diseases) multiply abnormally, leading to too much of a protein called immunoglobulin in bones and blood that crowds out healthy blood cells in the bone marrow. This damages the bones and eventually multiple organs as the disease worsens and spreads. B-cell maturation antigen (BCMA) is a protein found in high levels on multiple myeloma cells that promotes their survival and growth, making the cancer more aggressive and difficult to treat. Despite undergoing three to four therapies, many patients see their cancer return, highlighting the need for new treatments, especially those targeting BCMA. Lynozyfic was approved after a study with 80 people who had multiple myeloma and had already tried at least four other treatments. About 70% of them got better with Lynozyfic. Of those people, about 9 out of 10 were still doing well after nine months, and about 7 out of 10 were still doing well after a year. Scientists watched the patients for about 13 months. About 45% of patients receiving Lynozyfic had no measurable sign of cancer after treatment, according to a news release from Regeneron Pharmaceuticals, the drug's maker. 'The FDA approval of Lynozyfic is a welcome milestone. It provides appropriate multiple myeloma patients and their care teams with a novel patient-centric treatment option that includes a dosing schedule that can be adapted based on patient response,' said Diane Moran, interim CEO and senior vice president of strategic planning at the International Myeloma Foundation. Lynozyfic works by connecting special immune cells called T cells to cancer cells in the blood (multiple myeloma cells). This helps the T cells find and kill the cancer cells that usually hide from the immune system. Lynozyfic can be given quickly. It could be an option for people who can't get a similar but stronger treatment called CAR T therapy, which is harder to make and can have serious side effects. Lynozyfic is given through a drip into your vein. At first, people get three small doses that get bigger each time: 5 milligrams, 25 milligrams, and then 200 milligrams. After that, they get 200 milligrams once a week for 10 weeks, then once every two weeks. If they're doing well at week 24 and have had at least 17 doses, they can switch to once every four weeks. The most common side effects are bone or muscle pain, feeling tired, headache, cough, shortness of breath, weakness, diarrhea, and feeling sick to your stomach. Some serious side effects can happen, like a very strong immune reaction, problems from the infusion, or nerve damage. Because of these risks, patients may need to stay in the hospital for 24 hours after their first two doses. Lynozyfic is only given through a special safety program to help keep people safe. Other warnings include a higher chance of infections, low blood cell counts, liver problems, and harm to fetuses. People need to use birth control during treatment and for three months after their last dose. Patients should not drive, use heavy machines, or do dangerous activities for 48 hours after each first dose or if they have new nerve problems like confusion, shaking, or numbness until they feel better.
